Boehringer Ingelheim, Gubra to validate new Peptides for obesity

Boehringer Ingelheim, Gubra to validate new Peptides for obesity

Source: 
Pharmaceutical Business Review
snippet: 


Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.